Vericel to Present at the 18th Annual Morgan Stanley Global Healthcare Conference on Thursday, September 17, 2020
CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that
Nick Colangelo, President and CEO, will present the latest company overview at the 18th Annual Morgan Stanley Global Healthcare Conference. The conference is being conducted in a virtual
format and the presentation will take place on Thursday, September 17, 2020 at 2:45 p.m. Eastern Time.
A live webcast of the presentation will be available on the Investor Relations section of the Vericel Corporation website at: http://investors.vcel.com.
About Vericel Corporation
Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI (autologous cultured
chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee
with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater
than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid, a registration-stage biological orphan product for debridement of
severe thermal burns. For more information, please visit the company’s website at www.vcel.com.
Epicel and MACI are registered trademarks of Vericel Corporation. NexoBrid is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. 2020 Vericel Corporation. All rights reserved.
Lesen Sie auch
Investor Contacts:
Lee Stern
Solebury Trout
lstern@troutgroup.com
+1 646-378-2922